Reviewer's report

Title: Growth Inhibition of Anaplastic Thyroid Cancer by Opioid Growth Factor (OGF)

Version: 2 Date: 1 July 2009

Reviewer: Joshua Klopper

Reviewer's report:

- Major Compulsory Revisions

The authors provide a very comprehensive analysis of opioid growth factor and indicate how it may be a relevant endogenous tumor suppressor. I am not familiar of the appropriate “doses” of OPG in terms of receptor activation, the dose titration curve shows greater response at the higher doses, but the combo OPG and inhibitor study only evaluates blockade of effect at the lower dose (I believe 1µM). Are higher doses working via non-receptor mediated mechanisms? Will the inhibitor block higher dose effects to the same extent?

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

No competing interests